MedTrace Logo

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

NCT03232632 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-08-26

No results posted yet for this study

Summary

To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

Conditions

  • Cardiac Amyloidosis

Interventions

DRUG

PET with 18 F-Flutemetamol

PET with 18 F-Flutemetamol (Vizamyl ®)

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Eric OUHAYOUN, MD · University Hospital, Toulouse

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2019-09-15
Completion
2019-09-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03232632 on ClinicalTrials.gov